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Abstract
Imaging in clinical oncology trials provides a wealth of information that contributes to the drug devel-
opment process, especially in early phase studies. This paper focuses on kinetic modeling in DCE-MRI,
inspired by mixed-eﬀects models that are frequently used in the analysis of clinical trials. Instead of
summarizing each scanning session as a single kinetic parameter – such as median Ktrans across all voxels
in the tumor ROI – we propose to analyze all voxel time courses from all scans and across all subjects
simultaneously in a single model. The kinetic parameters from the usual non-linear regression model are
decomposed into unique components associated with factors from the longitudinal study; e.g., treatment,
patient and voxel eﬀects. A Bayesian hierarchical model provides the framework in order to construct a
data model, a parameter model, as well as prior distributions. The posterior distribution of the kinetic
parameters is estimated using Markov chain Monte Carlo (MCMC) methods. Hypothesis testing at the
study level for an overall treatment eﬀect is straightforward and the patient- and voxel-level parame-
ters capture random eﬀects that provide additional information at various levels of resolution to allow a
thorough evaluation of the clinical trial. The proposed method is validated with a breast cancer study,
where the subjects were imaged before and after two cycles of chemotherapy, demonstrating the clinical
potential of this method to longitudinal oncology studies.
2
1 Introduction
Assessing the eﬃcacy of cancer treatments using in vivo imaging is shifting from qualitative techniques
to quantitative imaging methods that characterize biologically relevant properties of tumor tissue. The
use of model-free or heuristic measures, such as the initial area under the Gadolinium curve (IAUGC), or
fully quantitative measures, such as the kinetic parameters from a compartmental model, are relatively
well understood in the analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
(1; 2; 3). Analysis of an oncology imaging trial is usually achieved by applying statistical summaries, such
as the mean or median, to the parameters of interest derived from tissue regions of interest (ROIs). That
is, enhancing (tumor) voxels are identified from the DCE-MRI data for each scan across all subjects and
those voxels are represented by a single parameter; e.g., Ktrans from quantitative analysis and IAUGC90
from a heuristic analysis. Hypothesis testing, either parametric or non-parametric, may then be applied
to the derived statistics in order to assess the eﬀects of treatment.
Applying statistical summaries to the kinetic parameter maps from DCE-MRI however discards a
substantial amount of information contained in the contrast agent concentration time curves (CTCs) at
each voxel, essentially abstracting thousands of observations in space and time to a single number per
scan per subject. We believe that there is a wealth of potential information by retaining the collection of
CTCs across all subjects and scans, at the same time acknowledging the fact that not all CTCs are the
same and not all patients are the same.
This paper proposes a Bayesian hierarchical model to analyze all tumor CTCs across all patients
and scans in a given study simultaneously based on the concept of a mixed-eﬀects model. Mixed-eﬀects
models are well established in the statistical community and have found widespread applications in, for
example, agriculture, economics, geophysics and the analysis of clinical trials (4; 5). Previous examples of
mixed-eﬀects models in neuroimaging primarily exist for functional MRI studies (6; 7; 8). Mixed-eﬀects
models extend the concept of traditional linear or non-linear models by combining both fixed eﬀects and
random eﬀects in the same model. More generally, mixed-eﬀects models are most often used to describe
relationships between the measured response and explanatory variables in data that are grouped according
to one or more factors. Fixed eﬀects denote parameters that are associated with an entire population
and random eﬀects denote parameters which are associated with random samples from a population. For
example, the drug or radiation therapy given in a trial is a fixed eﬀect, whereas patients are inherently
random because they are sampled from the general population. By acknowledging the fact that some
parameters are associated with random samples from a population, the results from a mixed-eﬀects model R1.5
may be generalized beyond the collection of subjects used in the specific clinical trial.
Bayesian methods are used here in the construction and estimation of the generalized additive model
(9; 10) that is associated with each kinetic parameter in the non-linear model of the CTCs. Similar
to mixed-eﬀects models in a maximum likelihood setting the variances associated with the fixed eﬀects
are chosen to be constant, but the variance terms associated with the random eﬀects are given prior
distributions. This leads to a shrinkage estimation of the random eﬀects so that they are pushed towards
3
zero (11). The fixed eﬀects in the model explain as much variance as possible, whereas the random eﬀects
capture variability that cannot be explained by the fixed eﬀects.
Formulation of a Bayesian hierarchical model is typically achieved in three stages: the data model, the
parameter model and the prior distributions (12; 13). The data model reflects our knowledge of the CTCs
at the voxel level using the class of compartmental models (14; 15; 16) with a standard arterial input
function (AIF) taken from the literature (17; 18; 19). The parameter model describes how parameters R1.1
from the compartmental model are associated with important factors of the clinical trial. At this stage
we decompose the kinetic parameters into treatment, patient and voxel eﬀects. We acknowledge that
this decomposition will depend on the specific features unique to the clinical trial design. Following from
Bayesian theory all parameters are regarded as random variables with pre-specified (prior) distributions.
This includes the parameters for the fixed as well as the random eﬀects in the model. Choices have been
made in the construction of the Bayesian hierarchical model in order to utilize eﬃcient sampling methods
wherever possible, and therefore reduce the computational burden.
The output from the Bayesian hierarchical model not only answers the basic question from a DCE-
MRI oncology study (i.e., did the treatment reduce Ktrans?) but also provides information about various
aspects of the study through the decomposition of the kinetic parameters. Posterior estimates for Ktrans
and kep are available to inspect the treatment eﬀect for each subject, averaged over the tumor region of
interest, for potential comparison with clinical endpoints. Estimates at the voxel level are also available
which allow one to separate spatial heterogeneity within a single region of interest with uncertainty in the
kinetic parameters due to a poor model fit. Estimates at the patient level may be used to compare imaging
biomarkers (kinetic parameters) with clinical endpoints, such as clinical response or clinical benefit. The
breast cancer study analyzed here illustrates the potential of this methodology by interrogating the output
from the hierarchical model at several levels.
2 Bayesian Hierarchical Model
Bayesian methods rely on the specification of prior distributions p(θ), that express our information
about the unknown parameters θ before any measurements are taken, and combine this information
with empirical evidence from direct observations in order to estimate those parameters. To assess the
model parameters after observing the data, the posterior distribution p(θ |Y) is computed, where θ is
the vector of all unknown parameters and Y is the vector of observations. The posterior distribution of
the parameter vector θ is obtained by applying Bayes’ theorem
p(θ |Y) = p(θ) ℓ(Y |θ)∫
p(θ∗) ℓ(Y |θ∗) dθ∗ , (1)
where ℓ(Y |θ) denotes the likelihood function of Y and p(θ) the product of all a priori probability
distribution functions. One can think of the posterior as an update to the prior distribution, our beliefs,
on θ after measuring a process – producing a mixture of previous knowledge and experimental data.
Examples of such Bayesian methodology in neuroimaging exists for functional MRI (20; 21) and also
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diﬀusion tensor imaging (22).
The following sections introduce the key components in the Bayesian hierarchical model: the data
model, the parameter model and the prior distributions. Each stage of the model development has been
tailored to the analysis of a longitudinal cancer treatment study with two time points. Figure 1 provides a
schematic overview of the proposed Bayesian Hierarchical Model (BHM). The three model stages are the
rows and the columns represent the “resolution” of the parameters. The kinetic parameters of interest
Ktrans and kep are decomposed into global (study-wide), subject and voxel eﬀects through the BHM,
while vp is simply estimated for each voxel without further decomposition. The measurement error term
is independent of the specific parameter model and involves both prior and hyperprior distributions. A
standard compartmental model is used to describe the concentration time curves observed at each voxel.
A generalized additive model (23) is proposed to decompose the kinetic parameters into factors that
are relevant to the design of the longitudinal study. Finally, the prior distributions, including necessary
hyperparameters, are specified on all factors of the parameter model (these terms will be explained in
detail subsequently). These prior distributions are relatively flat, reflecting a lack of knowledge concerning
the parameter, but also incorporate biological knowledge, such as a transfer rate must be non-negative,
or statistical knowledge, for example a variance must be non-negative.
2.1 Data Model
A hierarchical Bayesian framework is used to model the contrast agent concentration time curve (CTC)
of all voxels (24). Let Y = [Y (t1), Y (t2), . . . , Y (tT )]T denote the CTC associated with a single voxel
observed at T time points determined by the image acquisition protocol. The CTC is assumed to follow
a standard compartment model (19)
Ct(t) = vpCp(t) + Cp(t)⊗Ktrans exp(−t kep), (2)
where ⊗ denotes the convolution operator,Ktrans represents the transfer rate from plasma to extracellular
extravascular space (EES) per minute, kep the rate constant between EES and blood plasma per minute
and vp the vascular space fraction. The choice of model for the CTC depends on the scientific goals of the
study. Replacing Eq. [2] with a more or less complicated model is straightforward in our model-building R1.2
framework. The vector of observations Y may therefore be thought of as noisy measurements of the true
contrast agent concentration Ct(t), sampled at the discrete values t1, t2, . . . , tT to produce the vector
Ct = [Ct(t1), Ct(t2), . . . , Ct(tT )]T, given as a realization of a multivariate Normal distribution
Y ∼ NT
(
Ct,σ2IT
)
, (3)
where the notation Y ∼ NT (µ,Σ) means that the random variable Y comes from a multivariate Normal
distribution of dimension T with a mean vector µ and covariance matrix Σ.
We assume a common arterial input function (AIF), taken from the literature for all patients in the
study, and use a bi-exponential function (15)
Cp(t) = D[a1 exp(m1t) + a2 exp(m2t)], (4)
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where a1 = 24.0 kg/l, a2 = 6.20 kg/l, m1 = 3.00 min−1 and m2 = 0.016 min−1 are inspired by the work
of Fritz-Hansen et al. (18). A Bayesian implementation of the compartmental model above has been
previously proposed by Schmid et al. (25).
2.2 Parameter Model
The pharmacokinetic parameters from the data model are defined at every tumor voxel across all subjects
and scans. We assume a priori that the distribution of the random variables Ktrans and kep in the tumor
are patient-specific and are changed by treatment in a similar way. Therefore a generalized additive model
is used where the log-transformed kinetic parameters ψ1 = ln(Ktrans) and ψ2 = ln(kep) are expressed
as a linear combination of fixed- and random-eﬀects associated with identifiable factors in the study.
In addition to restricting both parameters to be positive, the log transform is appealing in this context
because individual terms in the additive model may be interpreted as a percentage change from baseline.
We assume that the distribution of the vascular fraction vp will not be modified by the treatment, but
individual vp values are allowed to change at the voxel level. Let i = 1, . . . , I denote the scans acquired
and let j = 1, . . . , J denote the patients, so that nij denotes the number of tumor voxels for patient j at
scan i, measured at T time points.
The factor of interest when measuring a change in the kinetic parameters (Ktrans or kep) is the
treatment eﬀect, or the diﬀerence between pre- and post-treatment visits in the study investigated here.
It is necessary to model the fact that substantial variability exists across patients in the study and between
the voxels in each region of interest (ROI) that describes the enhancing region in the dynamic acquisition.
Hence, the model for ln(Ktrans) is given by
ψijk1 = α1 + β1xi + γj1 + δj1xi + ϵijk1, for all i, j, k, (5)
where k denotes a unique voxel in the tumor ROI and
xi =
⎧⎨⎩ 0 scan i = 1 (pre-treatment);1 scan i = 2 (post-treatment). (6)
The parameter α1 is the factor of ln(Ktrans) associated with the baseline scan and β1 is the treatment
eﬀect (since it is only associated with the post-treatment acquisition). For the clinical study analyzed
here, the treatment eﬀect for Ktrans, as quantified via β1, is the key parameter of interest. A formal
hypothesis test will be performed on β1 in order to detect a significant reduction in Ktrans between the
pre- and post-treatment scans.
The parameters α1 and β1 are regarded as fixed eﬀects (the global column of Figure 1), and thus do
not vary between patients in the study. In the Bayesian framework, a marginal posterior distribution will
be available for each parameter. The parameter γj1 is the eﬀect of patient j on ln(Ktrans) and δj1 is the
interaction between patient j and treatment. Although the parameters α1 and β1 summarize information
for the baseline and treatment eﬀects of Ktrans across all subjects in the study, the parameters γj1 and
δj1 allow the estimate of Ktrans to adapt to the baseline and treatment eﬀects observed for each subject.
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These parameters are random eﬀects since each patient is assumed to be drawn from a larger population
of patients suﬀering from this condition (the subject column of Figure 1). Finally, the parameter ϵijk1 is
the random eﬀect of voxel k in scan i of patient j on ln(Ktrans). The voxel eﬀect models the fact that
each voxel in the tumor volume is drawn from a distribution that describes the ideal tumor voxel (the
voxel column of Figure 1). The combination of fixed and random eﬀects in a single model is commonly
referred to as a mixed-eﬀects model (9).
Using matrix notation, we can combine the generalized additive model across both kinetic parameters,
lnKtrans and ln kep, such that
ψijk = Zi
⎡⎣ φ
θj
⎤⎦+ ϵijk (7)
Xi =
⎡⎣ 1 xi 0 0
0 0 1 xi
⎤⎦ ; Zi = [Xi Xi]; φ =
⎡⎢⎢⎢⎢⎢⎢⎣
α1
β1
α2
β2
⎤⎥⎥⎥⎥⎥⎥⎦ ; θj =
⎡⎢⎢⎢⎢⎢⎢⎣
γj1
δj1
γj2
δj2
⎤⎥⎥⎥⎥⎥⎥⎦ ; ϵijk =
⎡⎣ ϵijk1
ϵijk2
⎤⎦ (8)
The scan-specific covariates in the model are captured in Zi, the fixed eﬀects are in φ, the patient-
specific random eﬀects are in θj and the voxel-specific random eﬀects are in ϵijk. The model formulation
in Eq. [7] can be adapted in order to incorporate additional covariates or a greater number of scans (e.g.,
in a longitudinal study).
2.3 Prior Distributions
In the Bayesian framework prior distributions with unknown variances are used to model the ran- R1.3
dom eﬀects (26). We use vector notation to denote the patient-specific random eﬀects such that γ =
[γ11, γ21, . . . , γJ1, γ12, . . . , γJ2]T and δ = [δ11, δ21, . . . , δJ1, δ12, . . . , δJ2]T, where we have dropped the ki-
netic parameter subscript to simplify the notation. We use multivariate Gaussian distributions to char-
acterize the prior distributions of the patient-specific random eﬀects; i.e.,
γ ∼ N2J
(
0, diag
(
τ 2γ
))
, (9)
δ ∼ N2J
(
0, diag
(
τ 2δ
))
, (10)
where τ 2γ and τ 2δ are vectors of the same length and indexed as γ and δ, respectively. The voxel-specific
random-eﬀect vectors are given unique prior distributions by scan, patient and parameter, so that each
vector is given by ϵijl = [ϵij1l, ϵij2l, · · · , ϵijnij l]T. We use a multivariate Gaussian prior distribution
ϵijl ∼ Nnij
(
0, τ2ϵ;ijlInij
)
, (11)
where nij is the number of voxels in the region of interest of scan i of patient j, and τ2ϵ;ijl is an unknown
variance associated with scan i, patient j and kinetic parameter l. Since the variances are unknown
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parameters, they must have their own prior distributions which are given by
τ 2γ
iid∼ IG(a, b), (12)
τ 2δ
iid∼ IG(a, b), (13)
τ 2ϵ
iid∼ IG(c, d), (14)
where a = b = c = 1, d = 10−5, and IG(·, ·) denotes the inverse Gamma distribution (27). Note, the
notation X iid∼ F means that all random variables Xi in the vector X are independently and identically
distributed from the distribution F . The inverse Gamma distribution is known as a conjugate prior for
the Normal distribution (12); i.e., the posterior distribution of γ given the variance τ2γ and all other
parameters (known as the full conditional distribution) is again a multivariate Gaussian distribution (see
the Appendix for further details). For the fixed eﬀects we use uniform priors so that the prior distribution
does not contain any relevant information, denoted by
p(αl) = p(βl) = constant for l = 1, 2. (15)
Note, the prior distributions on α and β are improper (not a valid probability distribution), but this is
not a problem since the full conditional distributions for both parameters are valid distributions (see the
Appendix).
The prior distributions on the coeﬃcients in the generalized additive model have been chosen so that
as much variance in the data as possible is explained by the fixed eﬀects α and β – as no prior information
is used for those parameters. Variability which cannot be explained by the fixed eﬀects will be covered
by the random eﬀects γ and δ. For these parameters an additional prior distribution (hyperprior) on the
variance of the parameters is defined which leads to a shrinkage of those eﬀects; that is, the parameters are
pushed towards zero and therefore do not cover variance explained by the fixed eﬀects. Any additional
variance is explained by the voxel eﬀects. Fig. 2 shows the prior probability density function for the
patient-specific eﬀects, exp(γ) and exp(δ), and for the voxel eﬀect exp(ϵ). The figure shows that the R1.7
prior distribution on the voxel eﬀects is quite informative and does a priori not allow the voxel eﬀect to
deviate much from baseline and patient specific eﬀect. The patient-specific eﬀects are less informative,
being stochastically restricted to the typical range of values for Ktrans and kep in breast cancer (28; 25).
The prior probability density function of α and β however can not be drawn, as both priors are uniform.
It is worth noting, that the prior distribution of ψ is also flat; i.e., there is no prior information on
log(Ktrans) and log(kep).
For the vascular space fraction we impose a relatively flat prior
vp;ijk
iid∼ B(e, f), for all i, j, k, (16)
with e = 1 and f = 19, where B(e, f) denotes the Beta distribution (29), so that the a priori expected
value of vp is e/(e + f) = 0.05. The Bayesian hierarchical model is complete by specifying a prior
distribution for the variance of the observational error in Eq. [3], with one variance parameter per scan
per patient,
σ2ij
iid∼ IG(g, h) for all i, j, (17)
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where g = 1 and h = 10−2. Note, the prior specification depends on the patient and scanning session but
is assumed to be the same across voxels.
3 Materials and Methods
3.1 Data acquisition
The first twelve patients from a previously reported breast cancer study are included in the analysis
(30; 25). Data were provided by the Paul Strickland Scanner Centre (PSSC) at Mount Vernon Hospital,
Northwood, UK. Each patient underwent a DCE-MRI study before and after two cycles of chemotherapy
(5-fluorouracil, epirubicin and cyclophosphamide). Six of these patients were identified as pathological
responders after receiving six cycles of chemotherapy, the others were non-responders.
For the calculation of T1 values, we used a two-point measurement with calibration curves as described
in (31; 32). The T1 values are computed as ratio of a T1-weighted fast low-angle shot (FLASH) image and
a proton density weighted (PDw) FLASH image. The imaging parameters of the T1-weighted FLASH
images were TR = 11 ms, TE = 4.7 ms, α = 35◦, and the parameters of the PDw FLASH images were
TR = 350 ms, TE = 4.7 ms, α = 6◦. Field of view was the same for all scans, 260 × 260 × 8 mm
per slice, so voxel dimensions were 1.016 × 1.016 × 8 mm. A scan consists of three sequential slices of
256 × 256 voxels and one slice placed in the contra lateral breast as control, which we do not use for
our analysis. A total of 40 to 50 acquisitions were acquired, with one acquisition each 11.9 seconds. A
dose of D = 0.1 mmol per kg body weight of Gd-DTPA was injected after the fourth scan using a power
injector with 4 ml/s with a 20 ml saline flush also at 4 ml/s. The first four scans, before contrast, were
used to compute T10 as the average of the T1 values of these images. Data from this study were acquired
in accordance with the recommendation given by (33). Informed consent was obtained from all patients.
Regions of interest (ROIs) were drawn manually by an expert radiologist on a scan-by-scan basis
using anatomical images and subtraction images from the dynamic data to define tumor voxels in pre-
and post-treatment scans.
3.2 Parameter Estimation via MCMC
The proposed Bayesian hierarchical model produces a joint posterior distribution of all parameters by
combining the data model (also known as the likelihood function), the parameter model and the prior
models (also known as the prior distributions), via Bayes theorem, Eq. [1]. Samples from the posterior
distribution may be assessed via Markov chain Monte Carlo (MCMC) (34). Samples from the joint poste-
rior distribution are used to obtain additional information on the accuracy and precision of the estimates.
For example, the standard error of the posterior distribution is the observational error. Statistics of
interest (e.g., the mean, median, quantiles, etc.) may be derived from the posterior distribution so that
not only point estimates but also confidence intervals are readily available for all parameters.
Implementation of the MCMC algorithm involved 25,000 iterations being drawn from the posterior
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distribution after an initial burn-in phase. To reduce computer storage, every 10th sample was used, pro-
ducing a total of 2500 samples to describe the posterior distribution. The sampling rate was determined
by visual inspection of the sample autocorrelation function. The burn-in phase involved 10,000 iterations;
after this the algorithm was judged to have converged to the invariant distribution and produce samples R1.4
from the posterior distribution that are independent from the initial starting conditions. The length of
the burn-in phase was determined by visual inspection of the sampled parameters. The analysis of the R1.11
full study took approximately 48 hours.
The global parameter φ and patient-specific parameters θj were drawn en bloc in Gaussian Gibbs
steps (35), and hyperparameters were drawn in independent Gamma Gibbs steps (technical details may
be found in the Appendix). Metropolis-Hastings steps with random walk proposals were necessary for
the voxel-specific random eﬀects and vascular space fraction. The algorithm was tuned to an acceptance
rate of 30-50% (36). Summary statistics were computed from the samples of the posterior distribution
to provide point estimates of the parameters from the generalized additive model. Empirical standard
errors, along with sample quantiles, were used to characterize the precision of the parameter estimates.
4 Results
All parameter estimates are derived from the posterior distribution using Bayes theorem. Hence, a
sampling distribution for each parameter value has been built up from which we produce a point estimate
via the median of the sample and also credible intervals (Bayesian confidence intervals) by using the
quantiles from their sampling distributions.
How the individual parameters from the generalized additive model coalesce to fit the observed con-
trast agent concentration time curve is illustrated, at the voxel level, in Figure 3. The observed CTCs
for two voxels from three subjects, one voxel at baseline and one voxel after treatment, are plotted along
with three fitted curves. The best estimate from the Bayesian hierarchical model at a specific voxel is
provided by the solid lines in each plot. That is, all parameters from the generalized additive model in
Eq. [7] are used in the parameter model in order to fit the data model. These curves are very similar
to, but not exactly the same as, model fits from the standard non-linear regression method used in the
quantitative analysis of DCE-MRI data (25). Removing the voxel-specific term from the model produces
a fitted curve that is associated with patient and treatment eﬀects, but not the specific voxel, and are
plotted as dashed lines in Figure 3. Given the presence of inter-voxel heterogeneity in the tumor ROI,
the dashed lines may or may not fit the observed data at a given voxel very well but they do represent
the best (in the sense of a posterior median) fit to all voxels in the tumor ROI for a given patient at a
single scan time point. Going back one more level in the generalized additive model and removing the
patient eﬀect leaves a fitted curve associated with the baseline and post-treatment scans (i.e., two curves
that summarize the overall treatment eﬀect) given by the dotted lines. The top row of Figure 3 contains
voxels from three subjects before treatment so the dotted lines are identical and represent the best (in the
sense of a posterior median) fit to all pre-treatment voxels across all subjects. The bottom row contains
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voxels from the same subjects after treatment and the dotted line is the best fit to all post-treatment
voxels.
Figure 4 shows the posterior distributions of pre-treatment (baseline) Ktrans and post-treatment
Ktrans. That is, the posterior samples were transformed via exp(α1) and exp(α1 + β1), respectively. For
ease of comparison between the two posterior distributions a smoothed version of each histogram, known
as a kernel density estimate (37) is displayed. The posterior median of Ktrans at baseline is 0.205, and
the posterior median of Ktrans after treatment is 0.156. Credible intervals for Ktrans, that cover 95% of
the posterior distribution, are [0.186, 0.234] at baseline and [0.121, 0.198] after treatment. That is, the
true value of Ktrans lies in the interval [0.186, 0.234] with posterior probability 0.95 at baseline and in
[0.121, 0.198] with posterior probability 0.95 after treatment.
The density estimates in Figure 4 are unimodal and indicate an overall decrease in Ktrans after
treatment. In order to test for a treatment eﬀect on Ktrans, specifically a reduction in Ktrans in the
second acquisition compared to the first, we construct the hypothesis
H0 : β1 > 0 versus H1 : β1 ≤ 0, (18)
using the treatment eﬀect from the parameter model in Eq. [7] and calculate the posterior probability
of β1 exceeding zero. From the results of the MCMC simulation, the null hypothesis is rejected with
p = 0.001.
When the generalized additive model was introduced previously the fact that the parameter Ktrans
and the covariates are linked through a logarithmic transform leads to the interpretation of individual
covariates in the parameter model as percentage changes from baseline instead of absolute changes. For
the treatment eﬀect this translates into a 100% · |0.7659− 1| = 23.3% median reduction in Ktrans from
baseline, where the sign determines whether the change is associated with an increase or decrease.
Figure 5 shows the patient-specific posterior distributions for pre-treatment Ktrans, given by exp(α1+
γj1) for j = 1, . . . , 12, and post-treatment Ktrans, given by exp(α1+β1+γj1+ δj1) for j = 1, . . . , 12. The
clinical responders are grouped in the first two columns of Figure 5 and the clinical non-responders are
in the third and fourth columns. The same range for x-axis [0, 0.45] was used in all plots of Ktrans for
comparison. In general the decrease inKtrans observed in the clinical responders is greater than the clinical
non-responders, but this is not absolute. For example, patient 12 shows only a small decrease in Ktrans
post-treatment and patient 6 shows an increase in Ktrans after treatment, but both are clinical responders
after additional chemotherapy. The interpretation of the treatment eﬀect as a percentage change from
baseline helps to quantify the results in Figure 5. The median percentage change in Ktrans for subject j
is obtained via 100% · | exp(βˆ1 + δˆj1) − 1|, where the sign determines whether an increase or decrease
occurred. For example, patient 1 (pathological responder) experienced a 100% · |0.7684 − 1| = 23.2%
median reduction in Ktrans which is very similar to the overall treatment eﬀect. This is definitely not the
norm as patient 9 experienced a 100% · |0.4285 − 1| = 57.2% median reduction in Ktrans and patient 6
experienced a 100% · |1.0817− 1| = 8.17% median increase in Ktrans, both were pathological responders.
Figure 6 shows the voxel-specific median posterior for pre- and post-treatment Ktrans. The clinical
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responders are grouped in the first two columns and the clinical non-responders are in the third and
fourth columns (identical to Fig. 5). The range for the x-axis was restricted to [0, 1] in all plots for
comparison. Given the number of samples from the posterior distribution across all voxels, the median
value of exp(α1 + γj1 + ϵ1jk1) for j = 1, . . . , 12; k = 1, . . . , n1j and exp(α1 + β1 + γj1 + δj1 + ϵ2jk1) for
j = 1, . . . , 12; k = 1, . . . , n2j across the 2500 samples, for each voxel k, was computed to summarize the
voxel eﬀect. The resulting histograms for the voxel eﬀect have been summarized by a kernel density
estimate. Most voxel-level distributions of median Ktrans show a substantial change in shape after
treatment, although this is more apparent in the responders compared to the non-responders.
It is interesting to note the extent of changes in the shape of these distributions across the diﬀerent
subjects. For example, patient 11 is characterized by a tumor with two distinct modes in estimated
Ktrans at baseline and a single mode after treatment. Looking at the statistical images of the median
posterior Ktrans at baseline the tumor ROI for patient 11 includes a substantial number of non-enhancing
voxels, in addition to those with reasonable Ktrans values, that are contributing to the bi-modal appear-
ance of the posterior distribution. The post-treatment tumor ROI is similar in size (i.e., number of
voxels), but the vast majority of voxels do not appear to be enhancing as measured by Ktrans. Hence,
a single mode is present in the posterior distribution. This variability, due to ROI definition, has been
previously documented (38). The distributions of median Ktrans for patient 8 show the reverse eﬀect,
albeit much more subtle than patient 11, where the post-treatment distribution of median Ktrans appears
to be bimodal but still spans a similar range of values. The statistical images of median Ktrans indicate
a tumor ROI with a highly perfused rim and substantial non-enhancing core at baseline, contributing to
the relatively wide histogram in Fig. 6. The post-treatment images have a greatly reduced tumor ROI
with a mixture of enhancing and non-enhancing voxels. Looking at the statistical images of the median
posterior Ktrans for this patient, the diﬀerence between pre- and post-treatment is likely to be due to
tumor compaction and the removal of dead cells caused by chemotherapy. Such large eﬀects in tumor size
are well documented in chemotherapy of breast cancer. In addition to the biological explanation, some
of the perceived diﬀerence may be attributed to the visualization technique used. The close proximity
of multiple peaks in the smoothed histogram of Ktrans makes it diﬃcult to draw firm conclusions since a
slightly wider smoothing kernel could eliminate this apparent feature and produce a broad single peak.
5 Discussion
Information is obtained at multiple levels during an imaging study in the clinical trial setting. The
main scientific question of interest is usually, was there a treatment eﬀect? This key hypothesis test
drives study design by influencing critical experimental design parameters such as power and sample
size. However, information at other levels, such as the patient or voxel level, can provide insight into
much more subtle features concerning patients, tumors and the treatment eﬀect. Patient variability with
application to predicting clinical response and tumor heterogeneity, as measured by voxel-wise properties
of the pharmacokinetic model, are just two examples of so-called secondary endpoints.
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The Bayesian hierarchical model presented here was developed to test the hypothesis of a treatment
eﬀect for an imaging study while acknowledging known sources of uncertainty; e.g., patients and voxels.
This is similar to the approach taken in standard analysis methods for clinical trials where fixed and
random eﬀects are identified in the model (5). The specification of such fixed and random eﬀects allows
the results from the study to be applicable beyond the patient population recruited for a specific study.
The results from all levels of the Bayesian hierarchical model have been presented using smoothed
histograms in order to convey information regarding the posterior distributions of the parameter esti-
mates. When interpreting the voxel-level results, spatial information (such as the spatial pattern of the
parameter estimate and the size of the tumor ROI) are lost in such a statistical summary. It is important
to also view the statistical images overlayed on suitable anatomical image in order to provide physiological
explanations for the observed shapes of the voxel-level posterior distributions. Even when drawn by an
experienced radiologist the tumor ROIs may substantially influence the quantitative results.
5.1 Comparison with Nonlinear Regression
A standard analysis was performed on the ROIs, using nonlinear regression to estimate the kinetic
parameters in the compartmental model over all voxels independently, and the median Ktrans values
have been summarized in Table 1. A non-parametric test (one-sided Wilcoxon signed rank test) was
performed to test that the diﬀerence between the median values was greater than zero; i.e., the treatment
did not reduce Ktrans across all subjects. The null hypothesis was rejected at a borderline significance
level (p = 0.055). Given the small sample size, N1 = 6 responders and N2 = 6 non-responders, this
is an impressive result and there is obviously a reasonable diﬀerence in Ktrans between the two groups.
Fig. 7 shows the kernel density estimates of Ktrans for each ROI, before and after treatment, using a
voxel-wise nonlinear regression analysis. That is, the compartmental model in Eq. [2] was fitted to each
voxel independently using the Levenberg-Marquardt optimization procedure. The empirical distributions
observed for each patient are extremely similar to those obtained in the BHM, Fig. 6. This is to be
expected given the relatively flat priors that were imposed on the kinetic parameters (25). The only R1.10
diﬀerence between Figs. 6 and 7 is the method of kinetic parameter estimation – Bayesian versus non-
linear regression.
While the voxel-wise results from the Bayesian and regression methods are very similar, and thus
provide a check on the consistency of the Bayesian model fitting procedure, the advantages of the Bayesian
hierarchical model are clear through the coeﬃcients from the generalized additive model in Eq. [7]. The
regression analysis can only summarize the study through Table 1, but the BHM allows one to isolate
and interrogate specific eﬀects, at the study or patient or voxel level, through the generalized additive
model. Examples of such interrogations have been presented here in Figures 4 and 5, but the possibilities
for such model summaries are only limited by the construction of the parameter model and design of the
clinical trial.
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5.2 Prior assumptions
Bayesian models rely on a priori beliefs about the model and parameters, expressed as prior distributions.
When combined with observed data, these beliefs are updated to reflect both sources of information. In
general, the use of relatively flat (uninformative) prior distributions produces a parameter estimates with
similar characteristics to those obtained from maximum-likelihood estimation, and hence similar results
overall. In the proposed Bayesian hierarchical model our prior beliefs are based on a mixed-eﬀect model
and follow suggestions in the Bayesian mixed-eﬀect literature (26) and in kinetic modelling in DCE-
MRI (28; 25). The baseline and treatment eﬀect are modelled as fixed eﬀects, and thus uniform priors
are used for those parameters. The patient-specific eﬀects and the voxel-specific eﬀect are modelled as
mixed eﬀects, where a Gaussian distribution with zero mean and unknown variance is used. This is
also known as shrinkage prior, as it shifts the parameters towards zero. The so-called hyperprior on
the unknown variance terms in these prior distributions determines how much variability is accumulated
by the fixed eﬀects versus the random eﬀects. Hence, the hyperpriors are chosen so that the baseline
and treatment eﬀects explain as much variability as possible. The patient-specific eﬀects accumulate
variability not explained by baseline and treatment and the voxel eﬀect accumulates variability not
explained by baseline, treatment or the patient-specific eﬀects. The prior on the voxel eﬀects is quite R1.10
informative and ensures that these eﬀects are only used when the fixed eﬀects, and the patient-specific
eﬀects, are unable to model the observed concentration time curve; i.e., the information contained in
the MR measurements must overcome the relatively strong prior specification. Fig. 8 depicts prior and R1.9
posterior distribution of patient-specific and voxel eﬀects. As previously mentioned the prior distribution
on the voxel eﬀects is informative, but the posterior distributions diﬀer substantially from the prior and
hence are driven by the observed data. For the patient-specific eﬀects, the prior is less informative and
again the information contained in the observed data produce posterior distributions with low variance
that diﬀer from the prior.
Specification of the hyperpriors was determined by a sensitivity analysis. For example, with an inverse
Gamma prior, with parameters a = b = 0.01, on the variance of the γ and δ parameters the algorithm
does not show any treatment eﬀect. The patient-treatment interaction term accumulates too much of
the variability, as the hyperprior is too conservative. The model was found to be insensitive to changes
in the specification of the hyperprior on ϵ, where values of d between 10−3 and 10−6 were found not to
impact the results.
The mixed-eﬀect model is built on top of a standard compartmental model used in DCE-MRI, and
we use the logarithms of Ktrans and kep in the specification. This transformation not only ensures
positive values for both parameters, but also allows the assumption that the transformed values are
Gaussian distributed (25). Hence, we can use a generalized additive model on those parameters. The
vascular fraction vp takes on values between zero and one, and hence we use a Beta distribution, with
hyperparameters e and f , such that the expected value of vp is 0.05. This value is appropriate for the
data involved in this study and in fact the model is relatively insensitive to the specification of this
particular prior distribution. A Beta distribution with e = f = 1 (i.e., a uniform distribution on [0, 1])
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does not change the results of the model. For the observational model, we use a Gaussian distribution
with unknown variance.
We did not use prior information to impose a specific relationship between Ktrans and kep; e.g., R1.12
Ktrans < kep. From a modelling point of view, the compartmental model is a rough approximation to the
physical system that is being investigated via DCE-MRI. At least two layers of abstraction sit between
the biological truth and what is measured in DCE-MRI as inferred via a parametric model: the data
acquired via MRI are imperfect measurements of the biological system because of the interaction between
physics and biology in the measurement process; and the fact that the “extended Kety model” is a gross
approximation to the underlying system. Hence, the kinetic parameters obtained from the extended
Kety model are relatively far removed from the biological processes and we feel it would be too restrictive
to enforce strict relationships between them in the BHM. In the results from the BHM on 12 subjects
presented here, we found that Ktrans was larger than kep in less than 1.5% of all voxels analyzed. These
were typically located at the edge of the tumor ROI, where perfusion characteristics often cause errors
in parameter estimation (2).
The signal intensity in magnitude MR images is known to be Rician, and approximately Gaussian for
moderate signal-to-noise values, but the distribution of the error of the contrast agent concentration is
a non-linear transformation of the observed signal intensities and, to the best of our knowledge, is not
known analytically. However, for positive values of contrast agent concentration in tissue a Gaussian
distribution seems appropriate. The hyperprior was determined by sensitivity analysis, and the model
was not found to be sensitive to changes in the specification of this hyperprior.
5.3 Modifications and Extensions
In this paper a generalized additive model was constructed for the kinetic parameters (Ktrans and kep)
in a compartmental model of a DCE-MRI oncology study. The model can easily be modified for other R1.6
kinetic parameters of interest; e.g., if the variable of interest in a study is the volume fraction of the EES
(ve = Ktrans/kep) or vp, which was handled as nuisance parameter in the study investigated here. The
framework can also be applied to other kinetic models (39; 40).
This model incorporated two scanning sessions, and all subjects, to asses the treatment eﬀect. The
modeling framework is easily extended to handle additional covariates or scanning sessions. For example,
a dose-ranging study design could be incorporated into the additive model where the treatment eﬀect
can be expressed as a function of the dose. Additional scans over time would enable the assessment of
temporal dependence on treatment and provide information about the reliability of the data by potentially
reducing the amount of uncertainty in the parameter estimates.
Another possible extension of this model would be to include the spatial information of adjacent voxels.
In the current implementation of the Bayesian hierarchical model all voxels from one region of interest
(tumor) were treated as spatially independent. Since voxel borders are arbitrary and do not represent
physiological boundaries between diﬀerent tissue types, it is likely that neighboring voxels share similar
perfusion characteristics. This fact has been taken advantage of in the context of Bayesian modeling of
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individual scans from a DCE-MRI study (25). The inclusion of a neighborhood structure in the modeling
process would reduce the uncertainty in estimation and provide more reliable estimates of the kinetic
parameters.
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A Appendix
A.1 Full conditional distributions
In each iteration of the MCMC (Markov chain Monte Carlo) algorithm, a random sample from the
marginal posterior distribution for all parameters is drawn. This is performed by sampling from the
conditional posterior distribution of one or more parameters given all other parameters and the data.
Hence, the full conditional distributions must be computed. The full conditional is denoted by θ | ·, where
θ is the parameter and · denotes all other parameters and the data. If the full conditional takes the from
of a standard distribution, one can sample directly form this distribution; this is known as the Gibbs
sampler (34). If the full conditional is not a standard distribution, then a Metropolis-Hastings sampler
must be constructed.
In the proposed Bayesian hierarchical model all full conditionals are from standard distributions due
to the use of conjugate prior distributions, except for the voxel eﬀect and vp. Let ξl = (αl,βl,γl, δl)
denote the vector of length P = I(J+1) associated with all parameters in the generalized additive model,
except the voxel eﬀect, for a specific kinetic parameter. The full conditional of ξl is a multivariate Normal
distribution given by
ξl | · ∼ NP
(
V−1m,V−1
)
,
m = [m1, . . . ,mP ]T,
mp =
2∑
i=1
J∑
j=1
(
τ−2ϵ;ij
nij∑
k=1
wijpψijkl
)
for p = 1, . . . , P ,
V = WTΛW+ diag (0, 0, τ−2γ;1l, . . . , τ
−2
γ;Jl, τ
−2
δ;1l, . . . , τ
−2
δ;Jl),
whereW is a I(J +1)×P matrix indicating which covariate should be included in the parameter model,
Eq. [7], and Λ is a diagonal matrix with elements nijτϵ;ij . The vector ξl is drawn in one block from a
multivariate Normal distribution with an eﬃcient block-sampling algorithm (41).
The full conditional distribution of the voxel eﬀect ϵijkl is a non-standard distribution. For computa-
tional reasons it is more convenient to sample from ψijkl rather than from ϵijkl, where the full conditional
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distribution of ψijkl is given by
p(ψijkl | ·) ∝ exp
(
− 1
2τ2ϵ;ijk
ψ2ijkl −
1
2σ2ij
(
Yijkl − Ŷijkl
)2)
. (19)
Note, Ŷijkl is the estimated contrast agent concentration curve given by the estimated model parameters
in ψˆijkl. Samples from this distribution are obtained using a Metropolis-Hastings step.
The full conditionals of all variance parameters are inverse Gamma distributions, which are given by
τ2γ | · iid∼ IG
(
a+ 1/2, b+ γ2jl
)
, (20)
τ2δ | · iid∼ IG
(
a+ 1/2, b+ δ2jl
)
, (21)
τ2ϵ | · iid∼ IG
⎧⎪⎨⎪⎩c+ 12
I∑
i=1
J∑
j=1
nij , d+
1
2
I∑
i=1
J∑
j=1
nij∑
k=1
⎛⎝Zi
⎡⎣ φ
θj
⎤⎦− ψijkl
⎞⎠2
⎫⎪⎬⎪⎭ . (22)
Hence, the variance parameters can be drawn independently using a Gibbs sampler.
References
[1] Padhani AR, Yarnold J, Regan J, Husband JE. Dynamic MRI of breast hardness following radiation
treatment. Journal of Magnetic Resonance Imaging 2003;17:427–434.
[2] Collins DJ, Padhani AR. Dynamic magnetic resonance imaging of tumor perfusion. IEEE Engineering
in Biology and Medicine Magazine 2004;65–83.
[3] Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HBW, Lee TY, Mayr
NA, Parker GJM, Port RE, Taylor J, Weiskoﬀ R. Estimating kinetic parameters from dynamic
contrast-enhanced T1-weighted MRI of a diﬀusable tracer: Standardized quantities and symbols.
Journal of Magnetic Resonance Imaging 1999;10:223–232.
[4] Pinheiro JC, Bates DM. Mixed-Eﬀects Models in S and S-PLUS. New York: Springer-Verlag, 2000.
[5] Brown H, Prescott R. Applied Mixed Models in Medicine. Chichester, UK: John Wiley & Sons, 1999.
[6] Beckmann CF, Jenkinson M, Smith SM. General multilevel linear modeling for group analysis of
fMRI. NeuroImage 2003;20(2):1052–1063.
[7] Friston KJ, Stephan KE, Lund TE, Morcom A, Kiebel S. Mixed-eﬀects and fMRI studies. NeuroIm-
age 2005;24:244–252.
[8] Roche A, Me´riaux S, Keller M, Thirion B. Mixed-eﬀect statistics for group analysis in fMRI: A
non-parametric maximum likelihood approach. NeuroImage 2007;38(3):501–510.
[9] Fahrmeir L, Lang S. Bayesian inference for generalized additive mixed models based on Markov
random field priors. Applied Statistics 2001;50:201–220.
[10] Fahrmeir L, Tutz G. Multivariate Statistical Modelling Based on Generalized Linear Models. New
York: Springer, 2nd edition, 2001.
17
[11] Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society
Series B 1996;58:267–288.
[12] Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. Boca Raton, Florida: Chapman
& Hall/CRC, 2nd edition, 2003.
[13] Wikle CK. Hierarchical models in environmental science. International Statistical Review 2002;
71:181–199.
[14] Kety S. Blood–tissue exchange methods. Theory of blood-tissue exchange and its application to
measurement of blood flow. Methods in Medical Research 1960;8:223–227.
[15] Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space
using dynamic MR imaging. 1. Fundamental concepts. Magnetic Resonance in Medicine 1984;
17(2):357–367.
[16] Larsson HB, Tofts PS. Measurement of the blood-brain barrier permeability and leakage space using
dynamic Gd-DTPA scanning—a comparison of methods. Magnetic Resonance in Medicine 1992;
24(1):174–176.
[17] Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of Gd-DTPA/dimeglumine after intrave-
neous injection into healthy volunteers. Physiological Chemistry and Physics and Medical NMR
1984;16:167–172.
[18] Fritz-Hansen T, Rostrup E, Larsson HBW, Søndergaard L, Ring P, Henriksen O. Measurement of
the arterial concentration of Gd-DTPA using MRI: A step toward quantitative perfusion imaging.
Magnetic Resonance in Medicine 1996;36:225–231.
[19] Buckley DL, Parker GJM. Measuring contrast agent concentration in T1-weighted dynamic contrast-
enhanced MRI. In A Jackson, DL Buckley, GJM Parker, eds., Dynamic Contrast-Enhanced
Magnetic Resonance Imaging in Oncology. Berlin: Springer, 2005; 69–80.
[20] Genovese CR. A Bayesian time-course model for functional magnetic resonance imaging data (with
discussion). Journal of the American Statistical Association 2000;95(451):691–719.
[21] Friston KJ, Penny W, Phillips C, Hinton G, Ashburner J. Classical and Bayesian inference in neu-
roimaging: Theory. NeuroImage 2002;16:465–483.
[22] Behrens TEJ, Woolrich MW, Jenkinson M, Johansen-Berg H, Nunes RG, Clare S, Matthews PM,
Brady JM, Smith SM. Characterization and propogation of uncertainty in diﬀusion-weighted MR
imaging. Magnetic Resonance in Medicine 2003;50:1077–1088.
[23] Hastie TJ, Tibshirani RJ. Generalized Additive Models. Chapman & Hall/CRC, 1990.
[24] Gelman A, Stern H, Carlin J, Rubin D. Bayesian Data Analysis. Chapman & Hall/CRC Press,
London/Boca Raton, 2003.
[25] Schmid VJ, Whitcher B, Padhani AR, Taylor NJ, Yang GZ. Bayesian methods for pharmacoki-
netic models in dynamic contrast-enhanced magnetic resonance imaging. IEEE Transactions on
Medical Imaging 2006;25(12):1627–1636.
18
[26] Clayton DG. Generalized linear mixed models. In WR Gilks, S Richardson, DJ Spiegelhalter, eds.,
Markov Chain Monte Carlo in Practice. Chapman & Hall, London, 1996; 275–301.
[27] Johnson NL, Kotz S, Balakrishnan N. Continuous Univariate Distributions, volume 1. New York:
John Wiley & Sons, 2nd edition, 1994.
[28] Parker G, Suckling J, Tanner S, Padhani A, Husband J, Leach M. MRIW: parametric analysis
software for contrast-enhanced dynamic MR imaging in cancer. Radiographics 1998;18:497–506.
[29] Johnson NL, Kotz S, Balakrishnan N. Continuous Univariate Distributions, volume 2. New York:
John Wiley & Sons, 1995.
[30] Ah-See MLW, Makris A, Taylor NJ, Burcombe RJ, Harrison M, Stirling JJ, Richman PI, Leach MO,
Padhani AR. Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in
primary breast cancer? Journal of Clinical Oncology (Meeting Abstracts) 2004;22(14S):582.
[31] Parker G, Suckling J, Tanner S, Padhani A, Revell P, Husband J, Leach M. Probing tumor mi-
crovascularity by measurement, analysis and display of contrast agent uptake kinetics. Journal
of Magnetic Resonance Imaging 1997;7:564–574.
[32] d’Arcy J, Collins D, Padhani A, Walker-Samuel S, Suckling J, Leach M. Informatics in radiol-
ogy (infoRAD): Magnetic resonance imaging workbench: analysis and visualization of dynamic
contrast-enhanced MR imaging data. Radiographics 2006;26(2):621–632.
[33] Leach MO, Brindle KM, Evelhoch JL, Griﬃths JR, Horsman MR, Jackson A, Jayson GC, Judson IR,
Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS,
Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P. The assessment of antiangiogenic
and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues
and recommendations. British Journal of Cancer 2005;92:1599–1610.
[34] Gilks WR, Richardson S, Spiegelhalter DJ, eds. Markov Chain Monte Carlo in Practice. Chapman
& Hall, London, 1996.
[35] Liu J, Wong W, Kong A. Covariance structure of the Gibbs sampler with applications to the com-
parisons of estimators and augmentation schemes. Biometrika 1994;81:27–40.
[36] Schmid VJ, Whitcher B, Yang GZ, Taylor NJ, Padhani AR. Statistical analysis of pharmacokinetical
models in dynamic contrast-enhanced magnetic resonance imaging. In J Duncan, G Gerig, eds.,
Medical Imaging Computing and Computer-Assisted Intervention – MICCAI 2005, number 3750
in Lecture Notes in Computer Science. Berlin: Springer, 2005; 886–893.
[37] Silverman BW. Density Estimation. London: Chapman & Hall, 1986.
[38] Beresford MJ, Padhani AR, Taylor NJ, Ah-See ML, Stirling JJ, Makris A, d’Arcy JA, Collins DJ.
Inter- and intraobserver variability in the evaluation of dynamic breast cancer MRI. Journal of
Magnetic Resonance Imaging 2006;24:1316–1325.
[39] StLawrence KS, Lee TY. An adiabatic approximation to the tissue homogeneity model for water
19
exchange in the brain: I. theoretical derivation. Journal of Cerebral Blood Flow & Metabolism
1998;18:1365–1377.
[40] Port RE, Knopp MV, Hoﬀmann U, Milker-Zabel S, Brix G. Multicompartment analysis of gadolin-
ium chelate kinetics: Blood-tissue exchange in mammary tumors as monitored by dynamic MR
imaging. Journal of Magnetic Resonance Imaging 1999;10:233–241.
[41] Rue H. Fast sampling of Gaussian Markov random fields. Journal of the Royal Statistical Society
Series B 2001;63:325–338.
20
Figure Captions
1. Schematic overview of the Bayesian hierarchical model for the observed contrast agent concentration
time curves.
2. Prior probability density functions for patient-specific eﬀects exp(γ) and exp(δ) (top) and voxel R1.7
eﬀects exp(ϵ) (bottom). The prior for the patient-specific eﬀects allows a deviation from the baseline
kinetic parameters in a range of biologically meaningful values. The prior distribution for the voxel
eﬀects only permits small deviations from the baseline.
3. Contrast concentration time curves (CTCs) for pre- and post-treatment scans in three diﬀerent
subjects. Solid lines indicate the voxel-specific fit to the CTC, dashed lines the combined patient-
and treatment-specific CTCs, and dotted lines the global pre- and post-treatment median CTCs
for the entire study.
4. Samples from the marginal posterior distributions of Ktrans at the study level. At pre-treatment
Ktrans is given by exp(α1) and at post-treatment Ktrans is given by exp(α1 + β1).
5. Samples from the marginal posterior distributions of Ktrans at the patient level. At pre-treatment
Ktrans is given by exp(α1 + γj1) for patient j and at post-treatment Ktrans is given by exp(α1 +
β1 + γj1 + δj1) for patient j.
6. Smoothed histograms summarizing the values of the posterior median Ktrans at the voxel level.
At pre-treatment Ktrans is given by exp(α1 + γj1 + ϵ1jk1) for scan 1, patient j and voxel k. At
post-treatment Ktrans is given by exp(α1 + β1+ γ1j + δ1j + ϵ12jk) for scan 2, patient j and voxel k.
The x-axis has been restricted to [0, 1] for visualization.
7. Smoothed histograms summarizing the values of Ktrans from voxel-wise non-linear regression anal-
ysis. The x-axis has been restricted to [0, 1] for visualization.
8. Prior (bold line) and posterior (thin lines) probability density functions for patient-specific eﬀects R1.9
γ (top) and voxel eﬀects ϵ (bottom). For the voxel-specific eﬀects, 25 random voxels from the
pre-treatment scan of patient 2 have been displayed.
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Table 1: Median Ktrans values from the standard analysis (R = responder, NR = non-responder).
Patient ID 1 2 3 4 5 6 7 8 9 10 11 12
pathological R R R NR NR R NR NR R NR NR R
pre 0.208 0.355 0.255 0.230 0.199 0.154 0.264 0.198 0.305 0.267 0.432 0.174
post 0.161 0.120 0.031 0.245 0.208 0.173 0.327 0.223 0.122 0.221 0.111 0.113
vpKtrans, kep
Beta-Prior
Voxel
flat prior Gaussian withunknown var.
D
at
a 
m
od
el
Pa
ra
m
et
er
 m
od
el
P
rio
r m
od
el
global subject voxel-specific
Gaussian with
unknown var.
Gaussian with
unknown var.
Hyperprior
for variance
Hyperprior
for variance
Hyperprior
for variance
Baseline
Treatment
Patient eff.
Interaction effect
Ct
Observation
ErrorY = +
Figure 1:
22
Probability density
Pa
tie
nt
 s
pe
ci
fic
 e
ffe
ct
s
0
1
2
3
4
5
Probability density
Vo
xe
l e
ffe
ct
s
0.
8
0.
9
1.
0
1.
1
1.
2
Figure 2:
23
Time in minutes
Co
nt
ra
st 
co
nc
en
tra
tio
n
0.0
0.1
0.2
0.3
0.4
0.5
0 1 2 3 4 5 6
Post treatment patient 1 Post treatment patient 2
0 1 2 3 4 5 6
Post treatment patient 3
Pre treatment patient 1
0 1 2 3 4 5 6
Pre treatment patient 2
0.0
0.1
0.2
0.3
0.4
0.5
Pre treatment patient 3
Figure 3:
Ktrans
Po
ste
rio
r D
en
sit
y
0
5
10
15
20
25
0.1 0.2 0.3
pre−treatment
post−treatment
Figure 4:
24
Ktrans
Po
ste
rio
r D
en
sit
y
0
200
400
600
0.0 0.1 0.2 0.3 0.4
Patient 1 Patient 2
0.0 0.1 0.2 0.3 0.4
Patient 4 Patient 5
Patient 3 Patient 6 Patient 7
0
200
400
600
Patient 8
0
200
400
600
Patient 9
0.0 0.1 0.2 0.3 0.4
Patient 12 Patient 10
0.0 0.1 0.2 0.3 0.4
Patient 11
pre−treatment
post−treatment
Figure 5:
Ktrans
Po
ste
rio
r D
en
sit
y
0
5
10
15
20
0.0 0.2 0.4 0.6 0.8 1.0
Patient 1 Patient 2
0.0 0.2 0.4 0.6 0.8 1.0
Patient 4 Patient 5
Patient 3 Patient 6 Patient 7
0
5
10
15
20
Patient 8
0
5
10
15
20
Patient 9
0.0 0.2 0.4 0.6 0.8 1.0
Patient 12 Patient 10
0.0 0.2 0.4 0.6 0.8 1.0
Patient 11
pre−treatment
post−treatment
Figure 6:
25
Ktrans
Po
ste
rio
r D
en
sit
y
0
5
10
15
0.0 0.2 0.4 0.6 0.8 1.0
Patient 1 Patient 2
0.0 0.2 0.4 0.6 0.8 1.0
Patient 4 Patient 5
Patient 3 Patient 6 Patient 7
0
5
10
15
Patient 8
0
5
10
15
Patient 9
0.0 0.2 0.4 0.6 0.8 1.0
Patient 12 Patient 10
0.0 0.2 0.4 0.6 0.8 1.0
Patient 11
pre−treatment
post−treatment
Figure 7:
26
Probability density
Pa
tie
nt
 s
pe
ci
fic
 e
ffe
ct
s
−2
−1
0
1
2
Probability density
Vo
xe
l e
ffe
ct
−3
−2
−1
0
1
2
3
Figure 8:
27
